JOHN R. GRAYBILL, M.D.; DAVID J. DRUTZ, M.D.
Treatment of systemic mycotic infections currently requires amphotericin B, miconazole, or flucytosine. All three agents have significant toxicity, and both amphotericin B and miconazole must be given intravenously, usually in a hospital setting. Flucytosine has a limited spectrum of activity, and the development of drug resistance by Candida and cryptococcal species is well documented. All three of these drugs have been the subjects of recent reviews (1-3).
There has been no generally available antifungal agent that is orally absorbable, nontoxic, and effective against etiologic agents of systemic mycoses. However, there is now in clinical trials an imidazole derivative that may
JOHN R. GRAYBILL, DAVID J. DRUTZ. Ketoconazole: A Major Innovation for Treatment of Fungal Disease. Ann Intern Med. 1980;93:921–923. doi: 10.7326/0003-4819-93-6-921
Download citation file:
Published: Ann Intern Med. 1980;93(6):921-923.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use